Format

Send to

Choose Destination
Curr Opin Immunol. 2005 Apr;17(2):187-94.

Breaking tolerance in cancer immunotherapy: time to ACT.

Author information

1
Department of Melanoma Medical Oncology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 904, Houston, Texas 77030, USA. woverwijk@mdanderson.org

Abstract

The discovery of defined tumor antigens and their application in therapeutic cancer vaccines has not yet resulted in a successful therapy for cancer patients. Recent data suggest that this might be because most current clinical immunotherapeutic strategies rely on a tolerized tumor-reactive T-cell repertoire, resulting in a weak T-cell response that cannot induce tumor regression in the face of a multitude of normal and tumor-induced immunoregulatory mechanisms. New insights from animal models and clinical trials suggest a rationale for combination approaches in which the ineffective endogenous anti-tumor immune response is enhanced through a combination of adoptive cell transfer (ACT), specific vaccination and cytokine help for the reliable induction of a robust anti-tumor immune response and tumor regression.

PMID:
15766680
DOI:
10.1016/j.coi.2005.01.011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center